New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents.

ABSTRACT: Developing peripherally active cannabinoid 1 (CB1) receptor antagonists is a novel therapeutic approach for the management of obesity. An unusual phenothiazine scaffold containing CB1R antagonizing hit was identified by adopting virtual screening work flow. The hit so identified was further modified by introducing polar functional groups into it to enhance the polar surface area and decrease the hydrophobicity of the resulting molecules. CB1 receptor antagonistic activity for the designed compounds was computed by the previously established pharmacophore and three dimensional quantitative structure-activity relationship models. Docking studies of these designed compounds confirmed the existence of favourable interactions within the active site of the CB1 receptor. The designed compounds we

SUBMITTER: Sharma MK 

PROVIDER: S-EPMC5785958 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature